These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26760231)

  • 1. Isolation of an HIV-1 neutralizing peptide mimicking the CXCR4 and CCR5 surface from the heavy-chain complementary determining region 3 repertoire of a viremic controller.
    Chevigne A; Delhalle S; Counson M; Beaupain N; Rybicki A; Verschueren C; Staub T; Schmit JC; Seguin-Devaux C; Deroo S
    AIDS; 2016 Jan; 30(3):377-82. PubMed ID: 26760231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.
    Xiang SH; Farzan M; Si Z; Madani N; Wang L; Rosenberg E; Robinson J; Sodroski J
    J Virol; 2005 May; 79(10):6068-77. PubMed ID: 15857992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide ligands selected with CD4-induced epitopes on native dualtropic HIV-1 envelope proteins mimic extracellular coreceptor domains and bind to HIV-1 gp120 independently of coreceptor usage.
    Dervillez X; Klaukien V; Dürr R; Koch J; Kreutz A; Haarmann T; Stoll M; Lee D; Carlomagno T; Schnierle B; Möbius K; Königs C; Griesinger C; Dietrich U
    J Virol; 2010 Oct; 84(19):10131-8. PubMed ID: 20660187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.
    Dogo-Isonagie C; Lam S; Gustchina E; Acharya P; Yang Y; Shahzad-ul-Hussan S; Clore GM; Kwong PD; Bewley CA
    J Biol Chem; 2012 Apr; 287(18):15076-86. PubMed ID: 22403408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
    Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
    PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of a CXCR4 antagonist from a human heavy chain CDR3-derived phage library.
    Chevigné A; Fischer A; Mathu J; Counson M; Beaupain N; Plesséria JM; Schmit JC; Deroo S
    FEBS J; 2011 Aug; 278(16):2867-78. PubMed ID: 21651727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
    Khurana S; Kennedy M; King LR; Golding H
    J Virol; 2005 Jun; 79(11):6791-800. PubMed ID: 15890918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism.
    Marcelino JM; Borrego P; Nilsson C; Família C; Barroso H; Maltez F; Doroana M; Antunes F; Quintas A; Taveira N
    AIDS; 2012 Nov; 26(18):2275-84. PubMed ID: 23151495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization.
    Willis JR; Finn JA; Briney B; Sapparapu G; Singh V; King H; LaBranche CC; Montefiori DC; Meiler J; Crowe JE
    Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4446-51. PubMed ID: 27044078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR5 N-terminus peptides enhance X4 HIV-1 infection by CXCR4 up-regulation.
    Dettin M; Zanchetta M; Pasquato A; Borrello M; Piatier-Tonneau D; Di Bello C; De Rossi A
    Biochem Biophys Res Commun; 2003 Aug; 307(3):640-6. PubMed ID: 12893271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
    Panos G; Watson DC
    Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
    Martín J; LaBranche CC; González-Scarano F
    J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of HIV Coreceptor Derived Peptides That Inhibit Viral Entry at Submicromolar Concentrations.
    Bobyk KD; Mandadapu SR; Lohith K; Guzzo C; Bhargava A; Lusso P; Bewley CA
    Mol Pharm; 2017 Aug; 14(8):2681-2689. PubMed ID: 28494151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
    Mild M; Kvist A; Esbjörnsson J; Karlsson I; Fenyö EM; Medstrand P
    Infect Genet Evol; 2010 Apr; 10(3):356-64. PubMed ID: 19446658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-immunized natural human heavy chain CDR3 repertoires allow the isolation of high affinity peptides mimicking a human influenza hemagglutinin epitope.
    Deroo S; Fischer A; Beaupain N; Counson M; Boutonnet N; Pletinckx J; Loverix S; Beirnaert E; De Haard H; Schmit JC; Lasters I
    Mol Immunol; 2008 Mar; 45(5):1366-73. PubMed ID: 17936360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR4-derived synthetic peptides inducing anti-HIV-1 antibodies.
    Hashimoto C; Nomura W; Narumi T; Fujino M; Nakahara T; Yamamoto N; Murakami T; Tamamura H
    Bioorg Med Chem; 2013 Nov; 21(22):6878-85. PubMed ID: 24119449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand selectivity of a synthetic CXCR4 mimetic peptide.
    Groß A; Brox R; Damm D; Tschammer N; Schmidt B; Eichler J
    Bioorg Med Chem; 2015 Jul; 23(14):4050-5. PubMed ID: 25801155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection.
    Chevigné A; Fievez V; Szpakowska M; Fischer A; Counson M; Plesséria JM; Schmit JC; Deroo S
    Biochim Biophys Acta; 2014 May; 1843(5):1031-41. PubMed ID: 24480462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.